Please assess the completion status of the following clinical trial:

Trial Title: Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Nasopharyngeal RT-PCR positive SARS-CoV-2 patient~2. Age 20-50 years~3. BMI 18-28 kg/m2~4. Informed consent~Exclusion Criteria:~1. Symptoms: Cough, fever, shortness of breath~2. O2 saturation by pulse-oximeter below 94%~3. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes~4. Arrhythmias and/or history of arrythmia~5. Psoriasis and/or history of psoriasis~6. Neuropathy or myopathy and/or history of these~7. Hypoglycemia and/or history of hypoglycemia~8. Pre-existing hepatic disease~9. Pre-existing renal disease~10. Use of antacids within 1 week~11. Use of antibiotics within 1 week~12. Pregnancy~13. RT-PCR performed \>3 days prior to enrollment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
- Arm 2 (Type: EXPERIMENTAL): Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
- Arm 3 (Type: ACTIVE_COMPARATOR): Chloroquine 500 mg BID for 5 days plus standard of care
- Arm 4 (Type: PLACEBO_COMPARATOR): Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)

Based on this trial design, predict the completion outcome and termination type (if applicable).